PCM
EW icon

Palisade Capital Management’s Edwards Lifesciences EW Stock Holding History

Palisade Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-42,264
Closed -$1.32M – 440
2017
Q1 		$1.32M Sell
42,264
-7,749
-15% -$243K 0.05% 297
2016
Q4 		$1.56M Sell
50,013
-7,776
-13% -$252K 0.06% 287
2016
Q3 		$2.32M Buy
57,789
+33,339
+136% +$1.26M 0.08% 309
2016
Q2 		$813K Buy
+24,450
New +$837K 0.03% 428

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Palisade Capital Management's EW Position: Q2 2017 in Review

Palisade Capital Management sold out of Edwards Lifesciences (EW) in Q2 2017, closing a stake of 42,264 shares — an estimated $1.32M sold.

Palisade Capital Management first reported a position in EW in Q2 2016 and held it in 4 quarters. The position peaked at $2.32M in Q3 2016. 720 funds tracked by Wall St. Rank hold EW as of Q2 2017.

  • Palisade Capital Management reported no remaining Edwards Lifesciences position as of Q2 2017 after selling out during the quarter.
  • Palisade Capital Management sold 42,264 Edwards Lifesciences shares in Q2 2017, an estimated $1.32M.
  • Palisade Capital Management first reported a position in Edwards Lifesciences in Q2 2016 and held it in 4 quarters.
  • Palisade Capital Management's Edwards Lifesciences position peaked at $2.32M in Q3 2016.
  • 720 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2017.

Based on Palisade Capital Management's 13F filing for Q2 2017, filed 1 Aug 2017.